NDAORALTABLET
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
GABITRIL (tiagabine hydrochloride) by Teva is mechanism of action the precise mechanism by which tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability, documented in in vitro experiments, to enhance the activity of gamma aminobutyric acid (gaba), the major inhibitory neurotransmitter in the central nervous system. First approved in 1997.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GABITRIL (tiagabine hydrochloride) is an oral small-molecule antiseizure medication approved in 1997 that enhances GABA activity in the central nervous system. It works by blocking the reuptake of GABA, the brain's primary inhibitory neurotransmitter, thereby increasing GABA availability at synaptic receptors. GABITRIL is indicated as adjunctive therapy for partial-onset seizures in patients with epilepsy.
$0.728MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal Medicare spend ($728K in 2023) and low claim volume signals a shrinking market footprint and contracted commercial team.
Mechanism of Action
Mechanism of Action The precise mechanism by which tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability, documented in in vitro experiments, to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the…
Worked on GABITRIL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.